- -

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)

Mostrar el registro completo del ítem

Iranzo, V.; Sirera Pérez, R.; Carrato, A.; Cabrera, A.; Jantus, E.; Guijarro, R.; Sanmartín, E.... (2011). Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04). Clinical & Translational Oncology. 13(6):411-418. doi:10.1007/s12094-011-0675-0.

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/65054

Ficheros en el ítem

Metadatos del ítem

Título: Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04)
Autor:
Entidad UPV: Universitat Politècnica de València. Departamento de Biotecnología - Departament de Biotecnologia
Fecha difusión:
Resumen:
[EN] Background: In advanced-stage (IIIB or IV) non-small-cell lung cancer (NSCLC), combination chemotherapy has demonstrated response rates of 20% and a 1-year survival rate of 30%. We conducted a multicentre, open-label, ...[+]
Palabras clave: EGFR , HTERT , Non-small-cell lung cancer , Pharmacogenomics , Sequential monotherapy , VEGF , Epidermal growth factor receptor , Gemcitabine , Paclitaxel , Telomerase reverse transcriptase , Vasculotropin , Adult , Advanced cancer , Aged , Alopecia , Anemia , Anorexia , Article , Blood toxicity , Cancer staging , Cancer survival , Chemotherapy induced emesis , Clinical article , Controlled study , Diarrhea , Dose response , Drug dose reduction , Drug dose sequence , Drug efficacy , Drug hypersensitivity , Drug tolerability , Drug withdrawal , Enzyme blood level , Fatigue , Febrile neutropenia , Female , Heart disease , Human , Lung non small cell cancer , Male , Monotherapy , Multicenter study , Multiple cycle treatment , Mutational analysis , Nausea , Neuropathy , Neutropenia , Oncogene K ras , Overall survival , Paresthesia , Peripheral neuropathy , Phase 2 clinical trial , Primary health care , Prognosis , Protein blood level , Quality of life , Sensory neuropathy , Survival time , Thrombocytopenia , Treatment duration , Treatment response , Adenocarcinoma , Antineoplastic Combined Chemotherapy Protocols , Carcinoma, Large Cell , Carcinoma, Non-Small-Cell Lung , Carcinoma, Squamous Cell , Deoxycytidine , Humans , Lung Neoplasms , Lymphatic Metastasis , Middle Aged , Neoplasm Recurrence, Local , Survival Rate , Treatment Outcome
Derechos de uso: Cerrado
Fuente:
Clinical & Translational Oncology. (issn: 1699-048X )
DOI: 10.1007/s12094-011-0675-0
Editorial:
Springer
Versión del editor: https://dx.doi.org/10.1007/s12094-011-0675-0
Tipo: Artículo

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro completo del ítem